| US 7,452,995 B2 | ||
| Aryl aniline β2 adrenergic receptor agonists | ||
| Edmund J. Moran, San Francisco, Calif. (US); John R. Jacobsen, San Mateo, Calif. (US); and James Aggen, Burlingame, Calif. (US) | ||
| Assigned to Theravance, Inc., South San Francisco, Calif. (US) | ||
| Filed on Apr. 07, 2005, as Appl. No. 11/102,197. | ||
| Application 11/102197 is a continuation of application No. 10/642926, filed on Aug. 18, 2003, granted, now 6,949,568. | ||
| Application 10/642926 is a continuation of application No. 10/292211, filed on Nov. 12, 2002, granted, now 6,653,323. | ||
| Claims priority of provisional application 60/338194, filed on Nov. 13, 2001. | ||
| Prior Publication US 2005/0192316 A1, Sep. 01, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07D 215/16 (2006.01); C07C 233/00 (2006.01) | ||
| U.S. Cl. 546—157 [546/159; 564/218; 564/360; 564/365] | 12 Claims |
1. A compound of formula (V):
 wherein:
R1 is methoxy or ethoxy, and R2 is hydrogen or phenyl; or R1 is hydrogen, and R2 is phenyl;
R3 is —CH2OH or —NHCHO, and R4 is hydrogen; or R3 and R4 taken together are —NHC(═O)CH═CH—;
Ra is hydrogen or an amino-protecting group; and
Rb is a hydroxy-protecting group.
|